Clinical Trial

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

Study acronym: DeLLphi-313
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.
Protocol Amendment History 3 changes
notable Trial sites expanded: 6 -> 22 locations 2026-08-04
critical Recruitment opened 2026-05-08
notable Trial sites expanded: 0 -> 3 locations 2026-05-08
Trial Details
NCT Number NCT07531095
Lead Sponsor Amgen
Conditions Small Cell Lung Cancer
Enrollment 160 participants
Start Date 2026-04-21
Primary Completion 2028-05-21 (estimated)
Study Completion 2031-05-21 (estimated)
Updated on ClinicalTrials.gov 2026-08-07